Similar changes were induced by Cladribine and by Gemcitabine, in the deoxypyrimidine salvage, during short term treatments

Zs Csapó, G. Keszler, M. Sasvári-Székely, K. Smid, P. Noordhuis, G. J. Peters, M. Staub

Research output: Contribution to journalArticle

5 Citations (Scopus)


Short term treatments (1-2 hrs) of human tonsillar lymphocytes by Cladribine (2-Chloro-deoxyadenosine, CdA) have suggested a new target for CdA, the inhibition of dCMP deaminase (Sasvari et al. 1994; BBRC 203, 1378). Further investigations have shown, that the dCMP-deaminase activity could be inhibited by 2-CI-dAMP in cell free extracts of lymphocytes. The pool size of dUMP (measured by an antibody against dUMP) was also decreased in WiDr colon cancer cells by CdA. The new antimetabolite against solid tumours, Gemcitabine (2',2'-difluoro-deoxycytidine, dFdC), had similar effects on the salvage of thymidine (dThd) and deoxycytidine (dCyd) as CdA. The Ki values for 3H-dThd and 3H-dCyd incorporation into DNA were 0.16 uM and 1.0 uM dFdC, respectively. The labeling of the TTP pool increased 6-7 times, while of dCTP pool only 1.5-1.7 times, suggesting a decrease of the size of corresponding pools. Similarly to CdA, the labeling as well as the concentration of dUMP was also decreased by dFdC. Both analogues are able to increase the deoxycytidine kinase activity, necessary for their phosphorylation and therapeutic action in cells. The target(s) for the two different drugs seems to be common.

Original languageEnglish
Pages (from-to)525-529
Number of pages5
JournalAdvances in experimental medicine and biology
Publication statusPublished - Jun 4 1998


ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this